Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review
Vaccines,
Journal Year:
2025,
Volume and Issue:
13(2), P. 159 - 159
Published: Feb. 6, 2025
Background:
New
strategies
for
respiratory
syncytial
virus
(RSV)
prevention
are
available
and
in
development,
but
their
acceptance
is
crucial
to
effectiveness.
Objectives:
This
systematic
review
aims
summarize
current
quantitative
qualitative
evidence
regarding
knowledge
attitudes
relating
RSV
prevention.
Methods:
Six
databases
(PubMed,
Scopus,
APA
PsycArticles;
PsycInfo;
CINAHL
Complete;
Psychology
Behavioral
Sciences
Collection)
two
preprint
repositories
(medRxiv
Preprints)
were
searched
up
until
23
December
2024
(PROSPERO:
CRD42024602351).
Results:
Sixty-one
articles
included,
focusing
on
vaccination
the
elderly
adults
at
risk
(n
=
10)
or
pregnant
people
24,
of
which
8
also
examined
preferences
maternal
vs.
infant
immunization)
immunization
27,
16
focused
palivizumab,
with
6
adherence
its
monthly
administration).
Eighteen
assessed
healthcare
professionals.
Overall,
findings
showed
limited
awareness
generally
positive
towards
moderate
high
intentions
uptake
rates.
Protection
against
disease
perceived
severity
promoted
acceptance,
whereas
concerns
about
side
effects
hindered
it.
Maternal
was
more
acceptable
than
immunization.
Conclusions:
Attitudes
options
favorable.
Should
become
available,
may
depend
characteristics,
how
they
framed
presented.
These
insights
highlight
importance
education
grounded
decision-making
literature,
while
recognizing
likely
favorable
reception
preventive
measures
across
target
age-populations.
Language: Английский
Respiratory syncytial virus immunization with nirsevimab: Acceptance and satisfaction assessment in infants and risk groups in the region of Murcia (Spain)
Jaime Jesús Pérez Martín,
No information about this author
María de la Cruz Gómez Moreno,
No information about this author
Susana Sánchez Manresa
No information about this author
et al.
Human Vaccines & Immunotherapeutics,
Journal Year:
2025,
Volume and Issue:
21(1)
Published: March 3, 2025
Respiratory
syncytial
virus
(RSV)
is
a
leading
cause
of
respiratory
infections
in
infants
under
two
years
age,
often
resulting
bronchiolitis
and
pneumonia,
which
contribute
to
high
hospitalization
rates.
The
recent
approval
nirsevimab,
long-acting
monoclonal
antibody,
has
provided
an
immunization
alternative
for
infants,
addressing
the
substantial
burden
RSV.
This
study
aimed
evaluate
acceptance
satisfaction
among
parents
or
legal
guardians
who
were
candidates
with
nirsevimab
Region
Murcia
(Spain)
during
2023–2024
campaign.
A
cross-sectional
survey,
encompassing
1692
immunized
219
non-immunized
revealed
rate
87%
indicating
willingness
immunize
future
child
86.6%
willing
recommend
it.
Concerns
about
safety
side
effects
primary
reasons
hesitation
did
not
their
infants.
These
findings
underscore
importance
enhancing
educational
efforts
campaigns
address
concerns,
thereby
supporting
broader
RSV
coverage
pediatric
population.
Language: Английский